Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Dose-ranging Study (LIPO-102-CL-11)

This study has been completed.
Information provided by (Responsible Party):
Neothetics, Inc Identifier:
First received: October 16, 2012
Last updated: March 5, 2015
Last verified: March 2015
Dose ranging study

Condition Intervention Phase
Abdominal Contour Defects
Drug: salmeterol xinafoate, fluticasone propionate
Drug: Placebo
Drug: salmeterol xinafoate
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Dose-ranging Study of the Safety and Efficacy of Fluticasone Propionate and Salmeterol Xinafoate in Healthy Patients With Abdominal Contour Defects

Resource links provided by NLM:

Further study details as provided by Neothetics, Inc:

Primary Outcome Measures:
  • Safety [ Time Frame: 8 weeks treatment ]
    physical exam, vital signs, clinical assessment of injection, clinical laboratory tests, and adverse events

  • Change in abdominal circumference [ Time Frame: Baseline to 9 weeks ]
    abdominal circumference

Secondary Outcome Measures:
  • Change in global clinician scale score [ Time Frame: Baseline to 9 weeks ]
  • Change in global patient scale score [ Time Frame: Baseline to 9 weeks ]
  • Change in Photonumeric scale score [ Time Frame: Baseline to 9 weeks ]
  • Change in Patient Reported Outcome Score [ Time Frame: Baseline to 9 weeks ]

Enrollment: 200
Study Start Date: August 2011
Study Completion Date: October 2012
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LIPO-102, Low Drug: salmeterol xinafoate, fluticasone propionate
Other Name: LIPO-102
Experimental: LIPO-102, Mid Drug: salmeterol xinafoate, fluticasone propionate
Other Name: LIPO-102
Experimental: LIPO-102, High Drug: salmeterol xinafoate, fluticasone propionate
Other Name: LIPO-102
Experimental: LIPO-102; Placebo Drug: Placebo
Experimental: salmeterol xinafoate Drug: salmeterol xinafoate


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • 18 - 45 years of age inclusive
  • abdominal contour defect
  • BMI <25 kg/msq
  • Stable diet and exercise and body weight

Exclusion Criteria:

  • Prior treatment of abdominal contour defects (liposuction, abdominoplasty, etc)
  • Known hypersensitivity to study drugs
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01712451

United States, California
Beverly Hills, California, United States
San Diego, California, United States
United States, New York
New York, New York, United States
United States, North Carolina
Raleigh, North Carolina, United States
United States, Tennessee
Nashville, Tennessee, United States
United States, Texas
Plano, Texas, United States
Sponsors and Collaborators
Neothetics, Inc
Study Director: Murray Maytom Neothetics, Inc
  More Information

Responsible Party: Neothetics, Inc Identifier: NCT01712451     History of Changes
Other Study ID Numbers: LIPO-102-CL-11
Study First Received: October 16, 2012
Last Updated: March 5, 2015

Keywords provided by Neothetics, Inc:

Additional relevant MeSH terms:
Salmeterol Xinafoate
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Anti-Allergic Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on April 28, 2017